Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 302
- 主要终点
- Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)
研究概览
简要总结
A major factor in the respiratory health of Cystic Fibrosis (CF) participants is the prevalence of chronic Pseudomonas aeruginosa (Pa) infections. The Pa infection rate in CF patients increases with age and by age 18 years approximately 85% of CF patients in the US are infected. Liposomal amikacin for inhalation (Arikayce™) was developed as a possible treatment for chronic infection due to Pa in CF patients.
The purpose of this study is to determine whether Arikayce™ is effective in treating chronic lung infections caused by Pa in CF participants. The effectiveness, safety, and tolerability of Arikayce™ will be compared to Tobramycin TOBI®, an inhalation antibiotic already available for use.
详细描述
CF is a genetic disease resulting from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Patients with CF manifest pathological changes in a variety of organs that express CFTR. The lungs are frequently affected often resulting in chronic infections by bacteria such as Pseudomonas aeruginosa and airway inflammation. Treatment of chronic lung infections is one of the principal goals of CF therapy. Arikayce™ LAI (liposomal amikacin for inhalation) is a sustained-release formulation of amikacin encapsulated inside nanoscale liposomal carriers designed for administration via inhalation. It is hypothesized that the sustained-release pulmonary targeting and biofilm penetration properties of this formulation will have several advantages over current therapies in treating CF patients with chronic lung infection caused by Pseudomonas aeruginosa.
This Phase 3 study has been designed to evaluate the efficacy, safety and tolerability of Arikayce™ in treating CF patients with chronic bronchopulmonary infection compared to a currently available antibiotic, TOBI® Inhalation Solution. Eligible participants will be randomized 1:1 to receive 590 mg of Arikayce™ once daily via a PARI Investigational eFlow® Nebulizer or 300 mg TOBI® BID via a PARI LC® PLUS nebulizer. Participants will receive 3 cycles of treatment with each cycle being comprised of 28 days on treatment followed by 28 days off-treatment. Total study duration is up to 186 days (~6 months) including an up to 18 day Screening period. Participants will be evaluated for safety, tolerability and efficacy bi-weekly during the first 4 weeks of treatment, and thereafter every 4 weeks for the duration of the study. Pharmacokinetics (PK) of Arikayce™ in blood, sputum and 24-hour urine will be determined in a subgroup of study participants who consent to PK evaluation.
At the completion of the TR02-108 protocol, participants who have consented and meet study safety criteria may enroll in the long-term, open-label, multi-cycle extension study of 590 mg of Arikayce™ (under a separate protocol TR02-110). Arikace™, Arikayce™, Liposomal Amikacin for Inhalation (LAI), and Amikacin Liposome Inhalation Suspension (ALIS) may be used interchangeably throughout this study and other studies evaluating amikacin liposome inhalation suspension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent or assent
- •Confirmed diagnosis of CF
- •History of chronic infection with Pseudomonas aeruginosa
- •Sputum culture positive for Pseudomonas aeruginosa at Screening
- •FEV1 ≥ 25% of predicted value at Screening
排除标准
- •FEV1 <25% of predicted at Screening
- •History of major complications of lung disease within 8 weeks prior to Screening
- •Hemoptysis of ≥60 mL in a 24-hour period within 4 weeks prior to Screening
- •History of positive culture for Burkholderia cepacia within 2 years prior to Screening
- •History of pulmonary tuberculosis or non-tuberculous mycobacterial lung disease treated within 2 years prior to Screening or requiring treatment at the time of screening
- •History of Allergic Broncho-Pulmonary Aspergillosis or any other condition requiring systemic steroids at a dose ≥ equivalent of 10 mg/day of prednisone within 3 months prior to Screening
- •Presence of any clinically significant cardiac disease
- •History of lung transplantation
- •Daily, continuous oxygen supplementation or nighttime supplemental oxygen requirement of greater than 2 L/min
- •Administration of any investigational products within 8 weeks prior to study Day 1
- •Smoking tobacco or any substance within 6 months prior to screening or anticipated inability to refrain from smoking throughout the study
研究组 & 干预措施
Arikayce™
Arikayce™ is liposomal amikacin for inhalation
干预措施: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. (Drug)
TOBI®
TOBI® is tobramycin inhalation solution
干预措施: Tobramycin inhalation solution using a PARI LC® Plus nebulizer. (Drug)
结局指标
主要结局
Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)
时间窗: Baseline to168 days
Relative Change (%) from baseline to end of study (Day 168) in FEV1 (1 second)
次要结局
- Number of Participants Experiencing a Pulmonary Exacerbation(168 days)
- Pumonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)(Baseline, Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168.)
- Number of Participants to First Antipseudomonal Antibiotic Treatment for Pulmonary Exacerbation(168 days)
- Number of Participants to First All Cause Hospitalization(168 days)
- Change in Density (Log CFU) in Pseudomonas Aeruginosa in Sputum(Baseline, Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168)
- Relative Percent (%) Change in Respiratory Symptoms as Measured by the CFQ-R(Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168)